Myojin Mayu, Horimoto Yoshiya, Ito Mayuko, Kitano Shigehisa, Ishizuka Yumiko, Sasaki Ritsuko, Uomori Toshitaka, Himuro Takanori, Murakami Fumi, Nakai Katsuya, Iijima Kotaro, Saito Mitsue
Department of Breast Oncology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
Breast Cancer. 2020 Jul;27(4):732-738. doi: 10.1007/s12282-020-01069-0. Epub 2020 Feb 27.
Metastatic breast cancer (MBC) is generally considered to be incurable. Although many options are available for treating MBC, physicians often encounter difficulties in choosing the most appropriate treatment because the MBCs of individual patients respond differently even to the same treatments. Thus, predictive markers for therapeutic efficacy are urgently needed. Neutrophil- and platelet-to-lymphocyte ratios (NLR and PLR, respectively), have been studied and established as prognostic markers for breast cancer patients but whether either or both of these markers are predictive of treatment responses is still unclear. Herein, we investigated predictive markers for eribulin-based treatment responsiveness in patients with MBC, by examining clinicopathological features, including several markers of immunocompetent cells in peripheral blood.
Clinicopathological features of the 104 patients with metastatic/Stage IV breast cancer given eribulin-based regimens were investigated in relation to clinical responses to eribulin-based treatments and progression-free-survival (PFS).
Special histological types and high NLR at baseline were independently related to poor clinical responses to the treatments (p = 0.023 and 0.039, respectively). The Cox hazard model revealed that patients with oestrogen receptor (ER)-negative tumours and high NLR, monocyte-to-lymphocyte ratio (MLR) and PLR showed significantly shorter PFS (p = 0.021, 0.005, 0.008 and 0.030, respectively). On multivariate analysis, only ER status and NLR remained independent factors related to PFS (p = 0.011 and 0.003, respectively).
Our data revealed that special histological types and high NLR might be factors related to low responsiveness to eribulin-based regimens in patients with MBC.
转移性乳腺癌（MBC）通常被认为是无法治愈的。尽管有多种治疗MBC的方法，但医生在选择最合适的治疗方案时常常遇到困难，因为即使接受相同治疗，个体患者的MBC反应也不同。因此，迫切需要治疗疗效的预测标志物。中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）已被研究并确立为乳腺癌患者的预后标志物，但这两种标志物是否能预测治疗反应仍不清楚。在此，我们通过检查临床病理特征，包括外周血中几种免疫活性细胞标志物，来研究MBC患者基于艾瑞布林治疗反应的预测标志物。
研究了104例接受基于艾瑞布林方案治疗的转移性/IV期乳腺癌患者的临床病理特征与基于艾瑞布林治疗的临床反应及无进展生存期（PFS）的关系。
特殊组织学类型和基线时高NLR与治疗的临床反应差独立相关（分别为p = 0.023和0.039）。Cox风险模型显示，雌激素受体（ER）阴性肿瘤且NLR、单核细胞与淋巴细胞比值（MLR）及PLR高的患者PFS显著缩短（分别为p = 0.021、0.005、0.008和0.030）。多因素分析显示，只有ER状态和NLR仍然是与PFS相关的独立因素（分别为p = 0.011和0.003）。
我们的数据显示，特殊组织学类型和高NLR可能是MBC患者对基于艾瑞布林方案反应低的相关因素。
